

Cagrilintide Dosing Chart

An investigational long-acting amylin analog for weight management, studied alone and in combination with semaglutide. Commonly discussed doses: 2.4 mg–2.4 mg. Trial protocols titrate to a once-weekly maintenance amount. Figures reflect published phase 2 dosing. This is investigational data, not a prescribing guide.

thelastpeptide.com · Medically reviewed by Charles Maddix, MSN, APRN, PMHNP-BC · Last reviewed 2026-08-02

FDA STATUS

Not FDA-approved for any use. Cagrilintide is an investigational drug in clinical development; it has not been approved.

5 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	2.4 mg
1 mL	5	48 u
2 mL	2.5	96 u
3 mL	1.67	—

10 mg vial — units to draw (U-100 syringe)

Water added	mg/mL	2.4 mg
1 mL	10	24 u
2 mL	5	48 u
3 mL	3.33	72 u

"—" means the draw exceeds one syringe at that concentration. Interactive calculator for any combination: thelastpeptide.com/peptides/cagrilintide

Cagrilintide dose figures are commonly discussed reference information with no approved labeling unless stated above. The Last Peptide is an educational reference and sells nothing. Dosing figures shown here are commonly discussed reference information, not prescriptions or medical advice. Many peptides listed are not FDA-approved. Talk to a licensed clinician before using any peptide.